cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
-
Contact Email
-
Phone
-
Journal Mail Official
-
Editorial Address
-
Location
Kota adm. jakarta barat,
Dki jakarta
INDONESIA
Universa Medicina
Published by Universitas Trisakti
ISSN : 19073062     EISSN : 24072230     DOI : -
Core Subject : Health, Science,
Health Professions Immunology & microbiology Medicine & Pharmacology Public Health
Universa Medicina (univ.med) is a four-monthly medical journal that publishes new research findings on a wide variety of topics of importance to biomedical science and clinical practice. Universa Medicina Online contains both the current issue and an online archive that can be accessed through browsing, advanced searching, or collections by disease or topic
Arjuna Subject : -
Articles 3 Documents
 1 
Search results for , issue " Vol 35, No 3 (2016)" : 3 Documents clear
Global viral hepatitis elimination by the year 2030 Tjan, Richard
Universa Medicina Vol 35, No 3 (2016)
Publisher : Faculty of Medicine, Trisakti University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18051/UnivMed.2016.v35.143-145

Abstract

According to a report by Stanaway et al.(1) in 2016, the absolute burden and relative rank of viral hepatitis increased between 1990 and 2013. For example, the number of global deaths due to viral hepatitis increased from 0.89 million to 1.45 million, indicating a need for its reduction. In this connection, on 28 May 2016 the 69th World Health Assembly adopted the global health sector strategy on viral hepatitis for the period 2016–2021,(2) as outlined in the report A69/32 of the Secretariat,(3) with the goal of eliminating viral hepatitis B and C by the year 2030. The global health sector strategy (GHSS) on viral hepatitis has constructed a roadmap toward the elimination of viral hepatitis B and C, targeting five priority prevention and treatment interventions. Prevention involves universal hepatitis B immunization of infants, prevention of mother-to-child transmission, increased injection safety and blood safety, and increased harm reduction, the implementation of which will contribute toward universal health coverage, which is the target for Goal 3 of the 2030 Agenda for Sustainable Development. In combination with treatment of chronic hepatitis, the goal is to achieve by the year 2030 a reduction in the incidence of viral hepatitis by 90% and mortality by 65%.(3,4)
Recombinant vascular endothelial growth factor 121 decreases vascular cell adhesion molecule-1 in murine pre-eclampsia model placenta Sulistyowati, Sri; Sondakh, John Arianto; Yuliantara, Eric Edwin; Respati, Supriyadi Hari; Soetrisno, Soetrisno
Universa Medicina Vol 35, No 3 (2016)
Publisher : Faculty of Medicine, Trisakti University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18051/UnivMed.2016.v35.192-198

Abstract

BackgroundPreeclampsia is one of the major contributors to maternal and fetal morbidity and mortality. Imbalance of soluble Fms-like tyrosine kinase (sFlt-1) as anti-angiogenic factor and vascular endothelial growth factor (VEGF) as pro-angiogenic factor plays a role in the pathogenesis of preeclampsia. Endothelial dysfunction in preeclampsia causes vascular cell adhesion molecule-1 (VCAM-1) to be expressed on its surface. This study aims to evaluate the effect of recombinant VEGF-121 on VCAM-1 expression in the placenta of a murine preeclampsia model. Methods An experimental analytical study conducted from February until March 2016 in the Biomedical Laboratory, Faculty of Veterinary Medicine, Airlangga University. The study sample consisted of 30 pregnant mice, divided into three groups, i.e. 10 normal pregnant mice, 10 mice with preeclampsia model and 10 mice with preeclampsia model and recombinant VEGF-121 therapy. All animals were subjected to immunohistochemical examination of VCAM-1 expression in their placentas. The results were assessed semiquantitatively according to a modified Remmele method. Data analysis was done using one-way ANOVA and Tukey’s multiple comparisons method. ResultsMean VCAM-1 expression in normal (0.97 ± 0.54%) murine placentas, compared with placentas (2.94 ± 0.96%) of murine preeclampsia models (p=0.000), while mean VCAM-1 expression in placentas of murine preeclampsia models with VEGF intervention was 2.14 ± 0.68% (p=0.030).Conclusion Recombinant VEGF-121 can reduce VCAM-1 expression in placentas of murine preeclampsia models. The present study has shown the potential benefits of VEGF therapy, justifying serious consideration of this therapeutic approach for use in women with preeclampsia.
Serum lactate as predictor and diagnostic biomarker of plasma leakage in adult dengue patients Bur, Rika; Suwarto, Suhendro; Santoso, Widayat Djoko; Harimurti, Kuntjoro
Universa Medicina Vol 35, No 3 (2016)
Publisher : Faculty of Medicine, Trisakti University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18051/UnivMed.2016.v35.213-221

Abstract

Background Dengue fever (DF) and dengue hemorrhagic fever (DHF) are differentiated by the occurrence in DHF of plasma leakage into the interstitial space as shown by pleural and peritoneal effusion, hemoconcentration, and intravascular hypovolemia. Perfusion dysfunction causes anaerobic metabolism, which leads to increased serum lactate. This study was to determine serum lactate as prognostic predictor and diagnostic biomarker of plasma leakage in adult dengue patients.Methods A cross-sectional retrospective cohort study was conducted on 57 adult dengue patients hospitalized in the internal medicine ward of Cipto Mangunkusumo Hospital and Persahabatan Hospital in Jakarta. Serum lactate was examined to determine its mean difference between DF and DHF. The data was analyzed by independent t-test and the cut-off points were identified for presence as well as absence of plasma leakage, then the receiver operating characteristics (ROC) curve was used to determine sensitivity and specificity.Results Mean serum lactate was significantly higher in DHF than in DF. From the ROC curve, the cut-off point for serum lactate as prognostic predictor on day 3 of fever was ³2.65 mmol/L with AUC of 0.626 (95% CI 0.480-0.772; p=0.108). The cut-off point for diagnostic biomarker of plasma leakage on day 5 of fever was 2.55 mmol/L with sensitivity 66.6%, specificity 54.2%, and AUC 0.668 (95% CI 0.550-0.826; p=0.016).Conclusion There was a significant difference in serum lactate between DF and DHF. In the critical phase, serum lactate of 2.55 mmol/L could be used as plasma leakage diagnostic marker of low accuracy.

Page 1 of 1 | Total Record : 3

 1 

Filter by Year

2016 2016


Reset
Filter By Issues
All Issue Vol. 44 No. 3 (2025): Ahead Of Print Vol. 44 No. 2 (2025) Vol. 44 No. 1 (2025) Vol. 43 No. 3 (2024) Vol. 43 No. 2 (2024) Vol. 43 No. 1 (2024) Vol. 42 No. 3 (2023) Vol. 42 No. 2 (2023) Vol. 42 No. 1 (2023) Vol. 41 No. 3 (2022) Vol. 41 No. 2 (2022) Vol. 41 No. 1 (2022) Vol. 40 No. 3 (2021) Vol. 40 No. 2 (2021) Vol. 40 No. 1 (2021) Vol 39, No 3 (2020) Vol. 39 No. 3 (2020) Vol. 39 No. 2 (2020) Vol 39, No 2 (2020) Vol 39, No 1 (2020) Vol. 39 No. 1 (2020) Vol 38, No 3 (2019) Vol 38, No 2 (2019) Vol 38, No 2 (2019) Vol 38, No 1 (2019) Vol 38, No 1 (2019) Vol 37, No 3 (2018) Vol 37, No 3 (2018) Vol. 37 No. 2 (2018) Vol 37, No 2 (2018) Vol 37, No 2 (2018) Vol 37, No 1 (2018) Vol 37, No 1 (2018) Vol 36, No 3 (2017) Vol. 36 No. 3 (2017) Vol 36, No 3 (2017) Vol 36, No 2 (2017) Vol 36, No 2 (2017) Vol 36, No 1 (2017) Vol 36, No 1 (2017) Vol 35, No 3 (2016) Vol 35, No 3 (2016) Vol 35, No 2 (2016) Vol 35, No 2 (2016) Vol 35, No 1 (2016) Vol 35, No 1 (2016) Vol. 35 No. 1 (2016) Vol 34, No 3 (2015) Vol 34, No 3 (2015) Vol. 34 No. 2 (2015) Vol. 34 No. 1 (2015) Vol. 33 No. 3 (2014) Vol. 33 No. 2 (2014) Vol. 33 No. 1 (2014) Vol. 32 No. 3 (2013) Vol. 32 No. 2 (2013) Vol. 32 No. 1 (2013) Vol. 31 No. 3 (2012) Vol. 31 No. 2 (2012) Vol 31, No 1 (2012) Vol. 31 No. 1 (2012) Vol 31, No 1 (2012) Vol 30, No 3 (2011) Vol 30, No 3 (2011) Vol 30, No 2 (2011) Vol 30, No 2 (2011) Vol 30, No 1 (2011) Vol 30, No 1 (2011) Vol 29, No 3 (2010) Vol 29, No 3 (2010) Vol 29, No 2 (2010) Vol 29, No 2 (2010) Vol 29, No 1 (2010) Vol 29, No 1 (2010) Vol 28, No 3 (2009) Vol 28, No 3 (2009) Vol 28, No 2 (2009) Vol 28, No 2 (2009) Vol 28, No 1 (2009) Vol 28, No 1 (2009) Vol 27, No 4 (2008) Vol 27, No 4 (2008) Vol 27, No 3 (2008) Vol 27, No 3 (2008) Vol 27, No 2 (2008) Vol 27, No 2 (2008) Vol 27, No 1 (2008) Vol 27, No 1 (2008) Vol 26, No 4 (2007) Vol 26, No 4 (2007) Vol 26, No 3 (2007) Vol 26, No 3 (2007) Vol 26, No 2 (2007) Vol 26, No 2 (2007) Vol 26, No 1 (2007) Vol 26, No 1 (2007) More Issue